JP2017105819A5 - - Google Patents

Download PDF

Info

Publication number
JP2017105819A5
JP2017105819A5 JP2017022249A JP2017022249A JP2017105819A5 JP 2017105819 A5 JP2017105819 A5 JP 2017105819A5 JP 2017022249 A JP2017022249 A JP 2017022249A JP 2017022249 A JP2017022249 A JP 2017022249A JP 2017105819 A5 JP2017105819 A5 JP 2017105819A5
Authority
JP
Japan
Prior art keywords
xaa
lys
gly
glu
ala
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2017022249A
Other languages
English (en)
Japanese (ja)
Other versions
JP6687557B2 (ja
JP2017105819A (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2017105819A publication Critical patent/JP2017105819A/ja
Publication of JP2017105819A5 publication Critical patent/JP2017105819A5/ja
Application granted granted Critical
Publication of JP6687557B2 publication Critical patent/JP6687557B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2017022249A 2013-07-04 2017-02-09 Glp−1様ペプチドの誘導体及びその使用 Active JP6687557B2 (ja)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP13175094.5 2013-07-04
EP13175094 2013-07-04
US201361845646P 2013-07-12 2013-07-12
US61/845,646 2013-07-12

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2015563070A Division JP6139712B2 (ja) 2013-07-04 2014-07-02 Glp−1様ペプチドの誘導体及びその使用

Publications (3)

Publication Number Publication Date
JP2017105819A JP2017105819A (ja) 2017-06-15
JP2017105819A5 true JP2017105819A5 (enExample) 2017-08-24
JP6687557B2 JP6687557B2 (ja) 2020-04-22

Family

ID=48703344

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2015563070A Active JP6139712B2 (ja) 2013-07-04 2014-07-02 Glp−1様ペプチドの誘導体及びその使用
JP2017022249A Active JP6687557B2 (ja) 2013-07-04 2017-02-09 Glp−1様ペプチドの誘導体及びその使用

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2015563070A Active JP6139712B2 (ja) 2013-07-04 2014-07-02 Glp−1様ペプチドの誘導体及びその使用

Country Status (11)

Country Link
US (2) US9498534B2 (enExample)
EP (1) EP3016975B1 (enExample)
JP (2) JP6139712B2 (enExample)
KR (1) KR20160029079A (enExample)
CN (1) CN105377884B (enExample)
AR (1) AR096789A1 (enExample)
AU (1) AU2014286234A1 (enExample)
BR (1) BR112015032875A2 (enExample)
CA (1) CA2916311A1 (enExample)
MX (1) MX2015016875A (enExample)
WO (1) WO2015000942A1 (enExample)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2014283221A1 (en) 2013-06-20 2015-12-03 Novo Nordisk A/S GLP-1 derivatives and uses thereof
JP6139712B2 (ja) * 2013-07-04 2017-05-31 ノヴォ ノルディスク アー/エス Glp−1様ペプチドの誘導体及びその使用
JP6730278B2 (ja) 2014-11-27 2020-07-29 ノヴォ ノルディスク アー/エス Glp−1誘導体及びその使用
EP3233898A1 (en) 2014-12-17 2017-10-25 Novo Nordisk A/S Glp-1 derivatives and uses thereof
US10118904B2 (en) 2015-06-05 2018-11-06 Vertex Pharmaceuticals Incorporated Triazoles for the treatment of Demyelinating Diseases
AU2016379403B2 (en) 2015-12-23 2020-03-12 The Johns Hopkins University Long-acting GLP-1r agonist as a therapy of neurological and neurodegenerative conditions
WO2017149070A1 (en) 2016-03-03 2017-09-08 Novo Nordisk A/S Glp-1 derivatives and uses thereof
ES2828526T3 (es) 2016-11-07 2021-05-26 Novo Nordisk As Esteres activos DCHBS de compuestos PEG y sus usos
WO2018106641A1 (en) 2016-12-06 2018-06-14 Vertex Pharmaceuticals Incorporated Pyrazoles for the treatment of demyelinating diseases
WO2018106643A1 (en) 2016-12-06 2018-06-14 Vertex Pharmaceuticals Incorporated Heterocyclic azoles for the treatment of demyelinating diseases
WO2018106646A1 (en) 2016-12-06 2018-06-14 Vertex Pharmaceuticals Incorporated Aminotriazoles for the treatment of demyelinating diseases
CN108976147B (zh) * 2017-05-31 2021-02-12 首都医科大学 氨基正己酰氨基甲环酰氨基正己酰碱性氨基酸,其合成,活性和应用
CN109248323B (zh) * 2017-07-14 2023-09-08 杭州先为达生物科技有限公司 酰化的glp-1衍生物
CN110945017B (zh) 2017-07-19 2024-07-16 诺和诺德股份有限公司 双功能化合物
BR112020002804A2 (pt) 2017-08-24 2020-07-28 Novo Nordisk A/S composição farmacêutica líquida, e, kit
JP7359358B2 (ja) * 2017-11-30 2023-10-11 グリアファーム エスエー 神経疾患の予防及び治療に使用するためのポリケチド化合物及びその誘導体
SMT202200352T1 (it) 2018-04-05 2022-09-14 Sun Pharmaceutical Ind Ltd Analoghi del glp-1 innovativi
WO2019200594A1 (zh) 2018-04-19 2019-10-24 杭州先为达生物科技有限公司 酰化的glp-1衍生物
CN115814063B (zh) * 2018-04-19 2026-07-28 杭州先为达生物科技股份有限公司 Glp-1衍生物及其治疗用途
CN113214382B (zh) * 2018-04-19 2024-01-19 杭州先为达生物科技股份有限公司 酰化的glp-1衍生物
JP6984753B2 (ja) * 2018-07-12 2021-12-22 三菱電機株式会社 半導体装置
WO2021136223A1 (en) 2019-12-31 2021-07-08 Beijing Ql Biopharmaceutical Co., Ltd. Fusion proteins of glp-1 and gdf15 and conjugates thereof
CN113728013B (zh) 2020-01-11 2022-06-14 北京质肽生物医药科技有限公司 Glp-1和fgf21的融合蛋白的缀合物
IL294521A (en) * 2020-02-18 2022-09-01 Novo Nordisk As glp-1 compounds and their uses
CA3193453A1 (en) 2020-09-30 2022-04-07 Beijing Ql Biopharmaceutical Co., Ltd. Polypeptide conjugates and methods of uses
CN116490212A (zh) * 2020-11-06 2023-07-25 诺和诺德股份有限公司 Glp-1前药及其用途
CN114685644A (zh) * 2020-12-29 2022-07-01 苏州康宁杰瑞生物科技有限公司 一种人glp-1多肽变体及其应用
WO2023284822A1 (en) 2021-07-14 2023-01-19 Beijing Ql Biopharmaceutical Co., Ltd. Fusion polypeptides for metabolic disorders
EP4323413A4 (en) 2022-03-30 2025-10-15 Beijing Ql Biopharmaceutical Co Ltd LIQUID PHARMACEUTICAL COMPOSITIONS OF POLYPEPTIDE CONJUGATES AND METHODS OF USE THEREOF
CN121001710A (zh) 2022-12-30 2025-11-21 阿尔吉法玛公司 提高口服多肽治疗剂的全身生物利用度的组合物和方法
GB202418179D0 (en) 2024-12-11 2025-01-22 Algipharma As Compositions and methods
GB202418172D0 (en) 2024-12-11 2025-01-22 Algipharma As Compositions and methods

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6458924B2 (en) * 1996-08-30 2002-10-01 Novo Nordisk A/S Derivatives of GLP-1 analogs
EP1060191B1 (en) * 1998-02-27 2010-04-28 Novo Nordisk A/S Derivatives of glp-1 analogs
CA2361830A1 (en) 1999-03-17 2000-09-21 Novo Nordisk A/S Method for acylating peptides and novel acylating agents
EP1076066A1 (en) * 1999-07-12 2001-02-14 Zealand Pharmaceuticals A/S Peptides for lowering blood glucose levels
EP1239871A1 (en) * 1999-11-12 2002-09-18 Novo Nordisk A/S Use of glp-1 agonists for the inhibition of beta cell degeneration
GB0020551D0 (en) 2000-08-22 2000-10-11 Birkett David Sprinkler system
US7557183B2 (en) 2003-03-19 2009-07-07 Eli Lilly And Company Polyethylene glycol linked GLP-1 compounds
TWI362392B (en) 2005-03-18 2012-04-21 Novo Nordisk As Acylated glp-1 compounds
SI1881850T1 (sl) 2005-05-13 2011-01-31 Lilly Co Eli Glp-1 pegilirane spojine
EP2514406A1 (en) 2007-06-01 2012-10-24 Novo Nordisk A/S Spontaneously dispersible preconcentrates including a peptide drug in a solid or semisolid carrier
US20100261637A1 (en) 2007-09-05 2010-10-14 Novo Nordisk A/S Peptides derivatized with a-b-c-d- and their therapeutical use
EP2190872B1 (en) 2007-09-05 2018-03-14 Novo Nordisk A/S Glucagon-like peptide-1 derivatives and their pharmaceutical use
US20100317057A1 (en) 2007-12-28 2010-12-16 Novo Nordisk A/S Semi-recombinant preparation of glp-1 analogues
US20110306551A1 (en) 2009-02-19 2011-12-15 Novo Nordisk A/S Modification of Factor VIII
US20120329711A1 (en) * 2009-12-16 2012-12-27 Nordisk A/S Glp-1 receptor agonist compounds with a modified n-terminus
JP6231386B2 (ja) 2010-11-09 2017-11-15 ノヴォ ノルディスク アー/エス リンカーを有する二重アシル化されたglp−1誘導体
AU2012241894B2 (en) 2011-04-12 2015-12-03 Novo Nordisk A/S Double-acylated GLP-1 derivatives
JP6139712B2 (ja) * 2013-07-04 2017-05-31 ノヴォ ノルディスク アー/エス Glp−1様ペプチドの誘導体及びその使用

Similar Documents

Publication Publication Date Title
JP2016523243A5 (enExample)
JP2016529253A5 (enExample)
JP2018505859A5 (enExample)
JP2019513126A5 (enExample)
JP2014529629A5 (enExample)
JP2014501712A5 (enExample)
JP2013543853A5 (enExample)
RU2013148921A (ru) Дважды ацилированные производные glp-1
US9546205B2 (en) Peptide analogues of glucagon and GLP1
JP4228398B2 (ja) 神経ペプチドy受容体拮抗剤
AU2011247824B2 (en) Glucagon-like peptide-1 analogue and use thereof
JP2008533105A5 (enExample)
JP2023071869A (ja) グルカゴンおよびglp-1受容体の長時間作用型コアゴニスト
EP2729493A1 (en) Novel compounds and their effects on feeding behaviour
JP7432361B2 (ja) ヒトインスリンまたはそのアナログのアシル化誘導体
RU2007134156A (ru) Ацилированные glp-1 соединения
JP2015517478A5 (enExample)
JP2015517477A5 (enExample)
RU2006144821A (ru) Пролонгирующие метки полипептидов, содержащие тетразольную группировку
RU2007134155A (ru) Glp-1 соединения с увеличенным временем полужизни
AU2014286234A1 (en) Derivatives of GLP-1 like peptides, and uses thereof
CN107205949A (zh) 包含片芯和立即释放包衣的用于口服glp‑1给药的药物组合物
US20100305139A1 (en) Method of treating abnormal lipid metabolism
AU2012210308A1 (en) Novel compounds and their effects on feeding behaviour
JP2007519642A5 (enExample)